Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Inclusion Criteria:

1. Patient who understood and voluntarily signed and dated an informed consent prior toany study-specific assessments/procedures being conducted

2. Adults patients (≥ 18-year-old at the time of signing the informed consent form; noupper age limit)

3. Eligible for any commercialized market authorized anti-CD19 CAR T-cells

4. Performance Status 0 or 1

5. With aggressive large B-cell lymphoma, including:

• diffuse large B-cell lymphoma

• Primary mediastinal B-cell lymphoma

• Any transformed follicular or marginal zone lymphoma

• high-grade B-cell lymphoma (HGBL) Note: patients with Central Nervous System (CNS) involvement could be included but not patients with primary CNS lymphoma

6. Available biopsy for centralized review

7. With a CAR T-cells indication as soon as 2nd line treatment no later than in 4thline, previously validated by the multidisciplinary tumor board Note: Any treatmentperformed prior to leukapheresis is considered a line of treatment

8. Total MetabolicTumor Volume (TMTV) > 80 ml, measured by centralized review, on 18FDG-PET (positron emission tomography) done just before starting CAR T-cellsprocedure (i.e., D-13 +/- 4 days before CAR-T cells infusion)

9. Creatinine clearance (as estimated by Modification of Diet in Renal Disease (MDRD)if > 60-year-old or Cockcroft-Gault if <60yo) >45 mL/min,

10. Adequate hepatic function:

• aspartate aminotransferase/alanine aminotransferase (ALT/AST) ≤ 3.0 x ULN. (Note: In the case of documented liver involvement by lymphoma, ALT/AST must be ≤ 5.0 x ULN)

• Serum total bilirubin ≤ 2.0 mg/dL (34 μmol/L) (Note: In the case of Gilbert'ssyndrome, or documented liver or pancreatic involvement by lymphoma, serumtotal bilirubin must be ≤ 3.0 mg/dL (51 μmol/L))

11. Patient covered by any social security system (France)

12. Patient who understands and speaks one of the country official languages, unlesslocal regulation authorizes independent translators

13. Contraception:

• For women of childbearing potential: Agreement to remain abstinent (refrainfrom heterosexual intercourse) or use two adequate methods of contraception,including at least one method with a failure rate of <1% per year, as soon asconsent is signed, during the treatment period (including periods of treatmentinterruption), and for at least 28 days after the last dose of golcadomide,Women must refrain from donating eggs during this same period.

Exclusion Criteria:

1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg,cervix, bladder, breast) unless disease free for at least 3 years

2. Presence or suspicion of fungal, bacterial, viral, or other infection that isuncontrolled or requiring IV antimicrobials for management; simple urinary tractinfection and uncomplicated bacterial pharyngitis are permitted if responding toactive treatment and after consultation with the sponsor's medical monitor

3. History of human immunodeficiency virus (HIV) infection or acute or chronic activehepatitis B or C infection; subjects with history of hepatitis infection must havecleared their infection as determined by standard serological and genetic testingper current Infectious Diseases Society of America guidelines or applicable countryguidelines

4. Significant pulmonary function impairment and oxygen saturation (SaO2) < 92% on roomair

5. Significant cardiovascular disease such as New York Heart Association Class III orIV or Objective Class C or D cardiac disease (see appendix 07)

6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,or other clinically significant cardiac disease within 6 months of enrollment

7. History of severe immediate hypersensitivity reaction to any of the agents used inthis study

8. Current treatment with strong CYP3A4/5 modulators (see appendix 13)

9. Pregnant, planning to become pregnant or lactating Women of Child Bearing Potential

10. Any significant medical conditions, laboratory abnormality or psychiatric illnesslikely to interfere with participation in this clinical study (according to theinvestigator's decision)

11. Person deprived of his/her liberty by a judicial or administrative decision

12. Person hospitalized without consent

13. Adult person under legal protection